Detalhe da pesquisa
1.
INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors.
Cancer Immunol Immunother
; 73(3): 44, 2024 Feb 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38349570
2.
Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors.
Cell Rep Med
; 4(1): 100868, 2023 01 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36513074
3.
Modulation of angiotensin II-mediated cardiac remodeling by the MEF2A target gene Xirp2.
Circ Res
; 106(5): 952-60, 2010 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-20093629
4.
Extracellular Vesicles as Biomarkers in Cancer Immunotherapy.
Cancers (Basel)
; 12(10)2020 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-33007968
5.
Characteristics and outcomes of lung cancer in solid organ transplant recipients.
Lung Cancer
; 146: 297-302, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32619780
6.
Combining chemotherapy with PD-1 blockade in NSCLC.
Pharmacol Ther
; 186: 130-137, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29352857
7.
PD-L1 as a biomarker in NSCLC: challenges and future directions.
Ann Transl Med
; 5(18): 375, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29057235
8.
Myomaxin is a novel transcriptional target of MEF2A that encodes a Xin-related alpha-actinin-interacting protein.
J Biol Chem
; 281(51): 39370-9, 2006 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-17046827